triple agonist glp-1 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data retatrutide triple agonist glp-1 gip
Description
These agents mimic the biological action of the native incretin hormone GLP-1 but are structurally modified to resist degradation by the enzyme dipeptidyl peptidase 4 (DPP-4), thereby extending their half-life and duration of action (Zheng et al., 2024
GLP-1 agonist drugs, which are synthetic versions of the naturally occurring GLP-1 hormone, have been used for decades in the treatment and management of Type II Diabetes Mellitus (T2DM)
You may also begin to notice a difference in hunger cues and appetite
Gamboa, J.L
